Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Apilimod mesylate
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
OrphAI Receives Orphan Drug Designation for AIT-101 in ALS Treatment in the EU
Details : AIT-101 (apilimod dimesylate) is a first-in-class, potent and highly selective inhibitor of the lipid kinase PIKfyve. It is being developed for the treatment of amyotrophic lateral sclerosis.
Product Name : AIT-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2024
Lead Product(s) : Apilimod mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
